

STATEMENT UNDER 37 CFR 3.73(b)

Atty. Docket No. 2159.2350003

Applicant/Patent Owner: Mitchell E. REFF et al.

Application No./Patent No.: 7,033,589 Filed/Issue Date: April 25, 2006

Entitled: Gamma-1 Anti-Human CD23 Monoclonal Antibodies and Use Thereof as Therapeutics

Biogen Idec MA Inc., a corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or  
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_%)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: See 1 in Addendum To: See 2 in Addendum  
The document was recorded in the United States Patent and Trademark Office at Reel 008608, Frame 0595, or for which a copy thereof is attached.
2. From: See 3 in Addendum To: BIODERMA INC.  
The document was recorded in the United States Patent and Trademark Office at Reel 015056, Frame 0921, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Andy Brookes Signature 9 March 2009 Date  
ANDY BROOKES Printed or Typed Name 6617-679-2000 Telephone Number  
VICE PRESIDENT, CHIEF IP COUNSEL Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.111 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Addendum

1. Mitchell E. REFF, William S. KLOETZER and Takehiko NAKAMURA
2. IDEC PHARMACEUTICALS CORPORATION AND SEIKAGAKU CORPORATION
3. IDEC PHARMACEUTICALS CORPORATION AND SEIKAGAKU CORPORATION